Enterprise Value

505.7B

Cash

2.941B

Avg Qtr Burn

N/A

Short % of Float

0.70%

Insider Ownership

0.15%

Institutional Own.

83.99%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Jardiance® (empagliflozin) (anti-SGLT2) Details
Diabetes, Type 2 diabetes, Chronic kidney disease

Approved

Quarterly sales

Jaypirca (pirtobrutinib) Details
Blood cancer, Cancer, Lymphoma, Mantle cell lymphoma

Approved

Quarterly sales

Donanemab Details
Alzheimer's disease

BLA

Acceptance for review

Mirikizumab Details
Ulcerative colitis

BLA

Resubmission

Retevmo Details
Medullary Thyroid Cancer

Phase 3

Data readout

Retevmo +/- pembrolizumab Details
Non-small cell lung carcinoma

Phase 3

Data readout

Remternetug Details
Alzheimer's disease

Phase 3

Data readout

Pirtobrutinib Details
Blood cancer, Cancer, Lymphoma, Chronic lymphocytic leukemia

Phase 3

Data readout

Mirikizumab Details
Crohns disease

Phase 3

Data readout

Phase 3

Data readout

Abemaciclib Details
Castration-resistant prostate cancer

Phase 3

Data readout

Phase 3

Data readout

Lebrikizumab Details
Skin disease/disorder, Atopic dermatitis

Phase 3

Update

Orforglipron Details
Type 1 diabetes

Phase 3

Update

Phase 3

Update

Phase 3

Update

Phase 3

Initiation

Peresolimab /LY3462817 Details
Rheumatoid arthritis, Autoimmune disease

Phase 2

Update

Phase 2

Update

AK-OTOF Details
OTOF-mediated hearing loss

Phase 1

Update